<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067077</url>
  </required_header>
  <id_info>
    <org_study_id>39587</org_study_id>
    <nct_id>NCT03067077</nct_id>
  </id_info>
  <brief_title>A Prospective, Contralateral, Eye to Eye Comparison of SMILE Surgery to LASIK Surgery</brief_title>
  <official_title>A Prospective, Randomized Comparison of SMILE Surgery to Wavefront-guided LASIK Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will undergo SMILE surgery in one eye and LASIK surgery in their other eye to&#xD;
      correct myopia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will have a comprehensive eye examination once they express an interest in the&#xD;
      study. This includes a slit lamp examination of the front of the eye and a dilated&#xD;
      fundoscopic examination of the back of the eye. If there is any pathology noted that would&#xD;
      exclude the subject from the study, then we will inform the patient and make an appropriate&#xD;
      referral. if the subject is deemed appropriate for the study after a comprehensive&#xD;
      examination included computerized videokeratography, then they can be enrolled. Subjects will&#xD;
      undergo bilateral simultaneous eye surgery. Which eye is treated with the WFG-LASIK and which&#xD;
      eye is treated with SMILE will be randomized so there is a 50% chance for either eye to&#xD;
      receive one treatment. Subjects will be seen on the day of surgery, post op day one, one&#xD;
      week, one month, three months, six months and one year. Subjects will receive topical&#xD;
      antibiotics in each eye for one week following the procedure. Subjects will receive topical&#xD;
      steroid ophthalmic drops for one week after treatment. Subjects will also receive topical&#xD;
      antibiotic ophthalmic drops for four days after treatment. All of this is within the usual&#xD;
      and customary standard of care for the treatment of subjects undergoing LASIK and SMILE&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2017</start_date>
  <completion_date type="Actual">March 15, 2021</completion_date>
  <primary_completion_date type="Actual">March 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uncorrected visual acuity</measure>
    <time_frame>One year</time_frame>
    <description>ETDRS testing lane</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CDVA</measure>
    <time_frame>One year</time_frame>
    <description>ETDRS testing lane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aberrometry measurements</measure>
    <time_frame>One year</time_frame>
    <description>iDesign aberrometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with validated questionnaire</measure>
    <time_frame>One year</time_frame>
    <description>PROWL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in corneal sensation</measure>
    <time_frame>One year</time_frame>
    <description>Cochet-Bonnet Aesthesiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dry eye symptoms and signs</measure>
    <time_frame>One year</time_frame>
    <description>Slit lamp examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vector analysis of astigmatism</measure>
    <time_frame>One year</time_frame>
    <description>Alpins method of analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior segment ocular coherence topography analysis</measure>
    <time_frame>One year</time_frame>
    <description>Humphrey Visante AS OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictability</measure>
    <time_frame>One year</time_frame>
    <description>Number of eyes within +/- 0.5 and +/- 1.00 diopter of the intended correction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability</measure>
    <time_frame>One year</time_frame>
    <description>Change in refractive error over 1 to 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>SMILE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SMILE surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wavefront-guided LASIK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wavefront-guided LASIK</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SMILE</intervention_name>
    <description>SMILE surgery</description>
    <arm_group_label>SMILE</arm_group_label>
    <arm_group_label>Wavefront-guided LASIK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LASIK</intervention_name>
    <description>LASIK surgery</description>
    <arm_group_label>SMILE</arm_group_label>
    <arm_group_label>Wavefront-guided LASIK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects age 22 and older with healthy eyes. Nearsightedness between -0.75 diopters&#xD;
             and -8.00 diopters.&#xD;
&#xD;
          -  Subjects with up to 3.00 diopters of astigmatism.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects under the age of 22.&#xD;
&#xD;
          -  Subjects with excessively thin corneas.&#xD;
&#xD;
          -  Subjects with topographic evidence of keratoconus.&#xD;
&#xD;
          -  Subjects with ectatic eye disorders.&#xD;
&#xD;
          -  Subjects with autoimmune diseases.&#xD;
&#xD;
          -  Subjects who are pregnant or nursing.&#xD;
&#xD;
          -  Subjects must have similar levels of nearsightedness in each eye. They can not be more&#xD;
             than 1.5 diopter of difference between eyes.&#xD;
&#xD;
          -  Subjects with 3.25 or more diopters of astigmatism&#xD;
&#xD;
          -  Subjects must have similar levels of astigmatism in each eye. They can not have more&#xD;
             than 0.50 diopters of difference between eyes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward E Manche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 16, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Edward E. Manche</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>SMILE</keyword>
  <keyword>LASIK</keyword>
  <keyword>Myopia</keyword>
  <keyword>Wavefront-guided</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

